Large-Scale flu vaccine safety study targets rare side effects

NCT ID NCT07710586

Completed ⭐️ VACCINE ⭐️ Sponsor: Ab&B Bio-tech Co., Ltd.JS Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study evaluates the safety of a quadrivalent subunit influenza vaccine in over 3,000 healthy individuals aged 3 years and older in Jiangsu Province, China. Researchers track rare adverse reactions, including cerebral infarction, and monitor side effects within 30 minutes, 7 days, and 28 days after vaccination, as well as serious events up to 6 months. The goal is to confirm the vaccine's safety profile in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a quadrivalent subunit influenza vaccine
What this could lead to: If successful, this study could confirm the safety profile of this flu vaccine in a large population, supporting its continued use.
What could go wrong: This is a post-marketing safety study, not a test of efficacy. It may detect rare side effects but cannot prove the vaccine prevents flu.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA VACCINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA VACCINE

Contacts and locations

Show contact details

Locations

Dongtai Center for Disease Control and Prevention

Dongtai, Jiangsu, 224200, China
Lianshui County Center for Disease Control and Prevention

Lianshui, Jiangsu, 223400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.